Skip to Content

Binosto Approval History

FDA Approved: Yes (First approved March 12, 2012)
Brand name: Binosto
Generic name: alendronate
Dosage form: Effervescent Tablets
Company: EffRx Pharmaceuticals SA
Treatment for: Osteoporosis

Binosto (alendronate) is a buffered effervescent dosage form of the bisphosphonate drug alendronate sodium administered once weekly for the treatment of osteoporosis.

Development History and FDA Approval Process for Binosto

DateArticle
Mar 15, 2012Approval FDA Approves Binosto, First and Only Effervescent Osteoporosis Treatment in a Buffered Solution
May 11, 2011First EffRx NDA Accepted for Filing by the FDA
Jan 10, 2011EffRx Pharmaceuticals SA Announces Submission of New Drug Application to FDA for Osteoporosis Treatment Targeting Increased Convenience for Patients

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide